STOCKS TELEGRAPH

Author: Hassan Masood

  • InVivo Therapeutics Holdings Corp. (NVIV) Stock on a Rise, Here’s Why

    InVivo Therapeutics Holdings Corp. (NVIV), a research and clinical-stage biotechnology company saw an increase of 12.31% in share price on Thursday. As a result, the price soared to $0.67. In the pre market, the NVIV stock is changing hands at $0.75, an increase of 12.61%.

    NVIV Q2 financial results

    On the 13th of August, InVivo (NVIV) released the quarterly results for the second quarter of the fiscal year 2021, which ended June 30th. According to those, the company had total assets of $258.14 million as of the 30th of June. The total operating expenses stood at $2.31 million, as compared to the operating expenses of $2.19 million during the equivalent period of 2020. The net loss for the quarter stood at $2.309 million, as compared to a net loss of $2.189 million during the equivalent period of 2020.

    Acceptance of preclinical module

    In Mid-July, InVivo Therapeutics (NVIV) announced that Federal Drug Administration (FDA) has accepted its preclinical module. That module was one of the three modules required by the company for its Human Device Exemption (HDE) application. The acceptance of HDE application by FDA depicted that FDA completed review of module and had no outstanding questions. Previously, FDA approved InVivo’s HDE modular shell submission as well as review process ofthe Neuro-Spinal Scaffold™ implant. The preclinical module is first one by the company to be submitted to FDA for review.  Richard Toselli, M.D., InVivo’s President and Chief Executive Officer, said on the occasion that InVivo values the FDA’s continued collaboration with it to help achieve the goal of complete HDE submission.

    Publication in Journal

    In February, the NVIV announced publication in peer-reviewed Journal of Neurosurgery: Spine. The review described the earlier presented six month primary endpoint results for the company INSPIRE 1.0 study. It titled “A study of probable benefit of a bioresorbable polymer scaffold for safety and neurological recovery in patients with complete thoracic spinal cord injury: 6-month results from the INSPIRE study.” Richard Toselli said on the occasion that it was rewarding for the company to see the INSPIRE 1.0 results published in Neurosurgery: Spine. He thanked all the patients who contributed in that regard.

    Impact of COVID-19 on NVIV

    Being a biotech company, InVivo (NVIV) didn’t face the effects of COVID as enormously as the ones associated with other sectors. Though revenue target was not achieved during the year, yet, the impact was not that much severe. Operational capability of the company got disturbed, and as a result, it didn’t produce the outcome which it was expected to produce. Annual and quarterly financial result depict that the company faced consequences of pandemic, yet, it didn’t got hit that much. With the easing government restrictions around the world, InVivo’s business is back on track of success.

    Future of NVIV stock

    Indicators are showing that NVIV stock could gain a positive momentum during near future. According to analysts, the company’s EPS during this year could grow by a massive 96.03%. So, potential investors should keep a close watch on NVIV stock future performance.

  • CDK Global Inc. (CDK) Stock in a decline in premarket, Here’s Why

    CDK Global Inc. (CDK), a multinational corporation known for providing software and technology solutions to the automotive sector, is seeing its share price plummeting in the premarket. Till the writing, CDK stock has decreased some 9.76%, and as a result, currently is changing hands at $41.05.

    Q4 and Yearly financial results

    The company announced quarterly results for fourth quarter of fiscal year 2021, as well as the results for fiscal year 2021 ended 30th June. The results for fourth quarter depict that the company generated revenue of $420.1 million during the quarter, an increase of 12% when compared with the fourth quarter’s revenue of 2020. The revenue recorded during the year stands at $1673.2 million. That is an increase of 2% when compared with the equivalent period of 2020. The total expenses for quarter stood at $318.4 million, as compared to $281.3 million during equivalent period of 2020. The operating expenses for year 2021, stood at $1247.9 million, as compared to 1139.3 million during equivalent period of 2020. Besides, the company declared regular quarterly cash dividend was $0.15 per share. It would be payable on 30th September 2021.  Commenting on the performance, Eric Guerin, CDK chief financial officer, said that based on current financial results, he believes the company is well positioned for future times.

    Arcade becoming member of CDK

    On 10th August, Arcade, a software company, announced to become a member of CDK Global Partner Program. This membership would bring Arcade workforce engagement solutions to the automotive industry. Arcade’s participation would bring it closer to the automotive dealers, which are keen to increase the productivity, as well as obtain other benefits.

    Carketa’s Membership

    In early July, Carketa, a leading dealership solutions software company, became a member of CDK Global Partner program. The integration of Carketa has the capability to push the CDK Global partner program through a streamlined system which in turn could push the sales of vehicles to a new level.

    Introduction of CDK Onepay

    In mid-June, CDK introduced CDK Onepay. CDK Onepay is a dealership-wide payment solution, and is fueled by Global Payments. CDK Onepay is designed to provide users with a smooth experience with regards to end to end payments. The Onepay also enables dealerships to request the payments, through aid of text, call through in person as well. It also provides dealerships with a facility to complete a totally integrated invoicing system. CDK Onepay is offered to the clients with no subscription fees.

    Q3 financial results

    In early May, CDK released quarterly results for third quarter of fiscal year 2021. According to details, the revenue recorded by the company during quarter stood at $433.1 million, an increase of 2% when compared with the revenue for equivalent period of 2020. The total expenses for quarter stood at $311.5 million, as compared to total expenses of $280.4 million during equivalent period of 2020.

    Future for CDK stock

    Looking ahead, it seems that the company is on track to attain financial stronghold in near future. The estimates say that company’s revenue for next year could stand at $121.54 million. The growth estimates depict that company could grow by 11.47% per annum during next 5 years. The EPS for this year could increase by 31.20%. All in all, based upon these statistics, potential investors should keenly watch CDK stock in near future.

  • Vivos Therapeutics Inc. (VVOS) Stock Soared in Premarket, Here’s Why

    Vivos Therapeutics Inc. (VVOS), a medical technology company, saw an increase in its share price in premarket, after VVOS stock gained some 5.79%, and closed the day at $3.56. In the last trading session, Vivos has experienced an increase of 16.84% in share price, and it currently stands at $3.36.

    Why did VVOS stock rose?

    VVOS stock soared on Tuesday after the company announced the detailed summary of national study results. These results were announced in mid of July. The summary revealed some positive developments for the company. As announced in the earlier results, 1 out of 4 patients having orofacial anomalies didn’t report any sort of Obstructive Sleep Apnea (OSA) symptoms. According to this more detailed summary, 20 patients had OSA. None of them reported worsening their OSA. Kirk Huntsman, Vivos’ Chairman, and CEO, said on the occasion that the investment community and other parties look for more real-world data about Vivos devices, so, the release of this detailed summary would be beneficial for the company.

    Announcement of quarterly and six month results

    On the 12th of August, Vivos Therapeutics Inc. (VVOS) announced the quarterly results for the second quarter of the fiscal year 2021, as well as the results for six month period, which ended June 30th. According to results, the company’s revenue increased to $4.5 million during the quarter, an increase of 37.5% when compared with the equivalent period of 2020. For the six-month period of 2021, it stood at $7.9 million, as compared to revenue of $6.5 million for the equivalent period of 2020. The gross profit during the quarter stood at $3.6 million, as compared to a gross profit of $2.7 million during the equivalent period of 2020. The gross profit for six month period stood at $6.3 million, as compared to the gross profit of $5.1 million during the first six-month period of 2020. The net loss for the quarter stood at $4 million, while for six month period, it stood at $7.4 million. Also, the company announced that during the second quarter of 2021, the number of patients treated by the Vivos system surpassed 19,000.

    Opening of the training center

    On July 29th, VVOS announced it has opened a training center in Denver, namely The Vivos Institute. The facility was initiated with the aim to provide dentists and healthcare professionals from around the world with postgraduate education and training. The healthcare teams would be guided about the treatment of OSA by Vivos and practicing tools related to Vivos. Kirk Huntsman said on the occasion that Institute’s opening represents a critical milestone for Vivos and Vivos is proud to have opened the institute as promised.

    Patients trust over company

    In early July, Vivos Therapeutics Inc. (VVOS) revealed that according to data from a patient study about Vivos treatment for dental anomalies, 97% of the patients said that they had obtained the desired result from the treatment of Vivos. The company said that the results are a powerful testimony about the efficacy of its treatment.

    Future for VVOS stock

    Estimates reveal that during next year, Vivos is expected to generate revenue of $27.8 million. The company is estimated to grow by 14.5% during next year. These results show that the financial performance of Vivos seems to be on a positive trend in near future. These developments in turn could have a substantive impact on VVOS stock. So, potential investors should keenly watch VVOS performance in the next few months.